Myasthenia Gravis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Myasthenia Gravis – Pipeline Review, H2 2017’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis

The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects

The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achillion Pharmaceuticals Inc

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Apellis Pharmaceuticals Inc

arGEN-X BV

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Company

CuraVac Inc

GlaxoSmithKline Plc

Grifols SA

HanAll Biopharma Co Ltd

Millennium Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Ra Pharmaceuticals Inc

Regenesance BV

Shire Plc

Toleranzia AB

UCB SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Myasthenia Gravis - Overview 7

Myasthenia Gravis - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Myasthenia Gravis - Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Myasthenia Gravis - Companies Involved in Therapeutics Development 24

Achillion Pharmaceuticals Inc 24

Akari Therapeutics Plc 24

Alexion Pharmaceuticals Inc 25

Alpha Cancer Technologies Inc 25

Apellis Pharmaceuticals Inc 26

arGEN-X BV 26

BioMarin Pharmaceutical Inc 27

Bristol-Myers Squibb Company 27

CuraVac Inc 28

GlaxoSmithKline Plc 28

Grifols SA 29

HanAll Biopharma Co Ltd 29

Millennium Pharmaceuticals Inc 30

Neurotune AG 30

Novartis AG 31

Pfizer Inc 31

Ra Pharmaceuticals Inc 32

Regenesance BV 32

Shire Plc 33

Toleranzia AB 33

UCB SA 34

Myasthenia Gravis - Drug Profiles 35

abatacept - Drug Profile 35

ACT-101 - Drug Profile 43

amifampridine phosphate - Drug Profile 45

APL-2 - Drug Profile 51

belimumab - Drug Profile 54

bortezomib - Drug Profile 61

CFZ-533 - Drug Profile 69

CVMG-01 - Drug Profile 71

eculizumab - Drug Profile 73

efgartigimod alfa - Drug Profile 83

GL-2045 - Drug Profile 86

HL-161 - Drug Profile 88

immune globulin (human) - Drug Profile 89

methotrexate - Drug Profile 91

NT-1654 - Drug Profile 92

RA-101495 - Drug Profile 93

Recombinant Protein for Myasthenia Gravis - Drug Profile 96

Recombinant Protein to Target CHRNA1 for Myasthenia Gravis - Drug Profile 97

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile 98

Regenemab - Drug Profile 99

rozanolixizumab - Drug Profile 100

SM-201 - Drug Profile 101

Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile 102

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 103

TK-21 - Drug Profile 104

Vaccine for Myasthenia Gravis - Drug Profile 105

Vaccine for Myasthenia Gravis - Drug Profile 106

Myasthenia Gravis - Dormant Projects 107

Myasthenia Gravis - Discontinued Products 108

Myasthenia Gravis - Product Development Milestones 109

Featured News & Press Releases 109

Appendix 119

Methodology 119

Coverage 119

Secondary Research 119

Primary Research 119

Expert Panel Validation 119

Contact Us 119

Disclaimer 120

List of Tables

List of Tables

Number of Products under Development for Myasthenia Gravis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Myasthenia Gravis – Pipeline by Achillion Pharmaceuticals Inc, H2 2017

Myasthenia Gravis – Pipeline by Akari Therapeutics Plc, H2 2017

Myasthenia Gravis – Pipeline by Alexion Pharmaceuticals Inc, H2 2017

Myasthenia Gravis – Pipeline by Alpha Cancer Technologies Inc, H2 2017

Myasthenia Gravis – Pipeline by Apellis Pharmaceuticals Inc, H2 2017

Myasthenia Gravis – Pipeline by arGEN-X BV, H2 2017

Myasthenia Gravis – Pipeline by BioMarin Pharmaceutical Inc, H2 2017

Myasthenia Gravis – Pipeline by Bristol-Myers Squibb Company, H2 2017

Myasthenia Gravis – Pipeline by CuraVac Inc, H2 2017

Myasthenia Gravis – Pipeline by GlaxoSmithKline Plc, H2 2017

Myasthenia Gravis – Pipeline by Grifols SA, H2 2017

Myasthenia Gravis – Pipeline by HanAll Biopharma Co Ltd, H2 2017

Myasthenia Gravis – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Myasthenia Gravis – Pipeline by Neurotune AG, H2 2017

Myasthenia Gravis – Pipeline by Novartis AG, H2 2017

Myasthenia Gravis – Pipeline by Pfizer Inc, H2 2017

Myasthenia Gravis – Pipeline by Ra Pharmaceuticals Inc, H2 2017

Myasthenia Gravis – Pipeline by Regenesance BV, H2 2017

Myasthenia Gravis – Pipeline by Shire Plc, H2 2017

Myasthenia Gravis – Pipeline by Toleranzia AB, H2 2017

Myasthenia Gravis – Pipeline by UCB SA, H2 2017

Myasthenia Gravis – Dormant Projects, H2 2017

Myasthenia Gravis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Myasthenia Gravis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports